MEDtube.net’s Post

Thoughtful discussion. Worth the read.

🚀 LINDERA at LSI Europe '24: Setting the Standard in AI and Healthcare LINDERA will be presenting at #LSIEurope24 this September in Portugal. As pioneers in AI since 2017, our mission is to transform elder care and healthcare with cutting-edge, affordable technology. What Sets Us Apart: 🤖 AI-driven Solutions: We leverage AI to deliver medicine that is not only top-tier but also accessible to everyone, everywhere. Our approach has turned software into a medical device (SaMD), setting new standards in healthcare. 💸 Price as Part of the Solution: In an overburdened elder care system, affordability is crucial. Our AI doesn't just support—it revolutionizes. 👵 From Seniors to AI Pioneers: Learning from the elderly has been akin to how Amazon learned from books. This knowledge has propelled us to lead in medical product innovation globally. 🕺 Innovation in Motion: Our precise 3D-movement analytics and large vision model technologies underscore our role as a hidden champion, offering SDK white label solutions that redefine what's possible in health tech. Join us as we showcase our transformative technologies and contribute to the future of global healthcare. 🔗 For more on the innovation lineup at LSI Europe ‘24, visit their website. #HealthTech #AI #ElderCare #GermanTech

Big thanks to Barnaby Pickering for the feature in Citeline's Medtech Insight and allowing me to share our vision for FastWave Medical and the advancements we're making in the intravascular lithotripsy (#IVL) space. Here’s what we touched on in the interview: 💪🏼 How FastWave is positioning itself in the >$9 billion IVL market. 🌉 How we’re solving for crucial gaps in current IVL offerings. 🏃🏽♂️ Some of the key milestons our team has recently achieved. Check out the full article here: https://lnkd.in/eK_gwG78 

AORTO ILIAC CTO - 2 days of loco-regional fibrinolysis (urokinase) from brachial access - recanalization and aorto iliac IVL bilaterally with Shockwave Medical 8/60 - kissing stent (self-expanding) Epic Boston Scientific 9/60 to save all collaterals (hypogastric, lumbar, IMA) with Cecilia Fenelli, Alessio Beconi

As we hit the #RoadToEurope we’re showcasing the innovators from around the globe who are selected to present at #LSIEurope24. Today we’re showcasing 3 innovators in Ireland selected to present at LSI Europe ‘24 in Portugal: 1. Declan Soden — Mirai Medical → Its ePORE therapy is a unique precision therapy platform that targets and destroy tumor tissue without harming surrounding healthy tissue. The minimally invasive technology delivers pulsed electrical fields that create pores in the cell membrane of tumor cells, catalyzing cellular death. Mirai's technology has been developed for external (skin) and internal (endoscopic) tumor treatment. 2. Finbar (Barry) Dolan — VERSONO MEDICAL LTD → Developing an intravascular ultrasonic platform to improve the crossing of severe occlusions in the peripheral vasculature. The device will prepare a working lumen to support endovascular therapy in patients with chronic total occlusions (CTOs) and critical limb ischemia (CLI). 3. Stephen Cox — InVera Medical → Developing a catheter-based therapy for chronic venous disease. The device uses non-thermal energy to disrupts the inner vessel lining, resulting in natural scarring and vessel closure that diverts blood flow away from diseased vessels. We look forward to seeing these innovators take the stage this September 16th - 20th in Portugal. Want to see what other innovators are presenting at LSI Europe ‘24? Head over to our website to see the first 100+ innovators selected to present.

Exciting news from Kardium Inc. in the fight against atrial fibrillation. The PULSE-EU trial tested Kardium Inc.'s novel PFA system called the Globe Pulsed Field System. The trial included 48 patients with paroxysmal or persistent AFib who underwent ablation targeting the pulmonary veins, posterior walls, and mitral isthmuses using this spherical array catheter. The results were highly promising: 💥 100% success rates for pulmonary vein isolation and posterior wall ablation  💥 91% success for mitral isthmus ablation 💥 Short procedure times (mean 87.8 minutes) 💥 84.2% freedom from atrial arrhythmia at 1 year for paroxysmal AFib 💥 80% freedom from atrial arrhythmia at 1 year for persistent AFib While still investigational and not yet FDA approved, the PULSE-EU trial data suggests the Globe PFA system could be a game-changer for catheter ablation. #EPeeps #EP #Electrophysiology #MedTech

This is our proposal for classification and terminology for interventional #EUS from JGES subcommittee🇯🇵 A step toward standardization but needs iteration as its procedures and devices keep growing

We are delighted to share an innovative advancement from Biosense Webster, Inc., a valued sponsor of our annual Cardiovascular Tech Forum. As part of Johnson & Johnson MedTech, Biosense Webster has introduced the CARTO™ 3 System Version 8. This latest version employs machine learning to enhance electro-anatomical maps for catheter ablation procedures, notably improving the efficiency and accuracy in treating conditions such as atrial fibrillation (AFib). The new system features sophisticated modules like CARTO ELEVATE™ and CARTOSOUND™ FAM, which integrate artificial intelligence to revolutionize mapping and ablation processes. This significant advancement in cardiac arrhythmia treatment underscores a commitment to precision and patient outcomes. Read more about how Biosense Webster is setting new standards in cardiac care: https://bit.ly/3wA2oH6 #CardiovascularTechForum #CTF2024 #HealthcareInnovation #MedicalTechnology #BiosenseWebster #JohnsonAndJohnson

🚀 Privileged to serve the medtech industry through my role at Integer! 👩⚕️🔬 The insights shared by Edward Arguello on neurovascular device development are spot-on. Addressing challenges early and partnering with experts can make all the difference. Check out the article: “Addressing the Challenges of Neurovascular Device Development—A Medtech Makers Q&A.” 💡👇 https://lnkd.in/gSfxE7Ya

We are happy to introduce Biosensors International Group, Ltd as silver sponsor at this year's ESAO Congress in Aachen, Germany. Biosensors International Group, Ltd develops, manufactures, and markets innovative Interventional Cardiovascular and Structural Heart technologies. Their PCI portfolio uses the patented Biolimus A9™, designed for coronary stent and balloon technologies to support healing and reendothelialization. In 2012, Biosensors began studying High Bleeding Risk (HBR) patients with only one month of DAPT mandated. To date, they have 14 publications from their landmark clinical trials, solidifying their status as HBR experts. Recently, Biosensors’ parent company invested in the structural heart disease field by acquiring NVT, the developers of the ALLEGRA™ Transfemoral TAVI system. This acquisition allows Biosensors to design and develop innovative transcatheter structural heart technologies, offering better solutions for Valvular Heart Disease patients. #Innovation #Cardiology #StructuralHeart #HighBleedingRisk #TAVI #Healthcare #esao